164 related articles for article (PubMed ID: 3444379)
21. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine.
Ahmad I; Filep JJ; Franklin JC; Janoff AS; Masters GR; Pattassery J; Peters A; Schupsky JJ; Zha Y; Mayhew E
Cancer Res; 1997 May; 57(10):1915-21. PubMed ID: 9157985
[TBL] [Abstract][Full Text] [Related]
22. Effects of ether lipid 1-O-octadecyl-2-methoxy-rac-glycero- 3-phosphocholine and its analogs PAF and CPAF on the release of nitric oxide in primary cultures of rat astrocytes.
Cardile V; Jiang X; Renis M; Bindoni M
Brain Res; 1996 Apr; 715(1-2):98-103. PubMed ID: 8739627
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells.
Hoffman DR; Hoffman LH; Snyder F
Cancer Res; 1986 Nov; 46(11):5803-9. PubMed ID: 3756924
[TBL] [Abstract][Full Text] [Related]
24. The effect of ether lipid 1-O-octadecyl-2-O-methoxy-rac-glycero-3-phosphocholine and its analogues platelet activating factor and carbamyl-platelet activating factor on the biosynthesis of interleukin-6 in human thymic epithelial cells cultivated in vitro.
Cardile V; Mascarucci P; De Simoni MG; Jiang X; Bindoni M
Cytokine; 1996 Sep; 8(9):698-701. PubMed ID: 8932980
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and growth inhibitory properties of glycosides of 1-O-hexadecyl-2-O-methyl-sn-glycerol, analogs of the antitumor ether lipid ET-18-OCH3 (edelfosine).
Marino-Albernas JR; Bittman R; Peters A; Mayhew E
J Med Chem; 1996 Aug; 39(17):3241-7. PubMed ID: 8765506
[TBL] [Abstract][Full Text] [Related]
26. Cyclic oxygen analogues of alkyl-lysophospholipids. Synthesis and neoplastic cell growth inhibitory properties.
Houlihan WJ; Lee ML; Munder PG; Winslow CM; Cheon SH; D'Aries FJ; DeLillo AK; Jaeggi CS; Mason RB; Parrino VA
J Lipid Mediat; 1990; 2(5):295-307. PubMed ID: 2133273
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of estradiol uptake and transforming growth factor alpha secretion in human breast cancer cell line MCF-7 by an alkyl-lysophospholipid.
Kosano H; Yasutomo Y; Kugai N; Nagata N; Inagaki H; Tanaka S; Takatani O
Cancer Res; 1990 Jun; 50(11):3172-5. PubMed ID: 2334912
[TBL] [Abstract][Full Text] [Related]
28. Superoxide production by macrophages stimulated in vivo with synthetic ether lipids.
Schreiber BM; Layne MD; Modest EJ
Lipids; 1994 Apr; 29(4):237-42. PubMed ID: 8177017
[TBL] [Abstract][Full Text] [Related]
29. The CoA-independent transacylase in PAF biosynthesis: tissue distribution and molecular species selectivity.
Blank ML; Smith ZL; Fitzgerald V; Snyder F
Biochim Biophys Acta; 1995 Feb; 1254(3):295-301. PubMed ID: 7857969
[TBL] [Abstract][Full Text] [Related]
30. Metabolism of platelet-activating factor (PAF; 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and lyso-PAF (1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine) by cultured rat Kupffer cells.
Chao W; Siafaka-Kapadai A; Hanahan DJ; Olson MS
Biochem J; 1989 Jul; 261(1):77-81. PubMed ID: 2775221
[TBL] [Abstract][Full Text] [Related]
31. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
Komuro Y; Imanishi N; Uchida M; Morooka S
Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of alkyl chain-modified ether lipids and evaluation of their in vitro cytotoxicity.
Fos E; Suesa N; Borras L; Lobato C; Banfi P; Gambetta RA; Zunino F; Mauleón D; Carganico G
J Med Chem; 1995 Mar; 38(7):1216-28. PubMed ID: 7707324
[TBL] [Abstract][Full Text] [Related]
33. Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Chabot MC; Wykle RL; Modest EJ; Daniel LW
Cancer Res; 1989 Aug; 49(16):4441-5. PubMed ID: 2743333
[TBL] [Abstract][Full Text] [Related]
34. Increased membrane permeability for an antitumoral alkyl lysophospholipid in sensitive tumor cells.
Storch J; Munder PG
Lipids; 1987 Nov; 22(11):813-9. PubMed ID: 3444371
[TBL] [Abstract][Full Text] [Related]
35. Conversion of alkylacetylglycerol to platelet-activating factor in HL-60 cells and subcellular localization of the mediator.
Vallari DS; Record M; Snyder F
Arch Biochem Biophys; 1990 Feb; 276(2):538-45. PubMed ID: 2154953
[TBL] [Abstract][Full Text] [Related]
36. Lack of enantio-selectivity in the in vitro antitumour cytotoxicity and membrane-damaging activity of ether lipid SRI 62-834: further evidence for a non-receptor-mediated mechanism of action.
Lohmeyer M; Workman P
Biochem Pharmacol; 1992 Aug; 44(4):819-23. PubMed ID: 1510728
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues.
Seewald MJ; Olsen RA; Sehgal I; Melder DC; Modest EJ; Powis G
Cancer Res; 1990 Aug; 50(15):4458-63. PubMed ID: 2369723
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and antineoplastic properties of ether-linked thioglycolipids.
Guivisdalsky PN; Bittman R; Smith Z; Blank ML; Snyder F; Howard S; Salari H
J Med Chem; 1990 Sep; 33(9):2614-21. PubMed ID: 2391700
[TBL] [Abstract][Full Text] [Related]
39. Factors that influence the proportions of platelet-activating factor and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine synthesized by the mast cell.
Triggiani M; Fonteh AN; Chilton FH
Biochem J; 1992 Sep; 286 ( Pt 2)(Pt 2):497-503. PubMed ID: 1530582
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo cytotoxicity of alkyl lysophospholipid ET-18-OCH3 and thioether lipid BM 41.440.
Leder GH; Fiebig HH; Wallbrecher E; Winterhalter BR; Löhr GW
Lipids; 1987 Nov; 22(11):958-61. PubMed ID: 3444393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
